Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1176/ajp.153.4.581 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Discount pharmacies may save patients significant money on androgenetic alopecia medications compared to both traditional pharmacies and direct-to-consumer companies.
J Am Acad Dermatol
March 2025
Department of Dermatology, Lewis Katz School of Medicine, Temple University, Philadelphia, PA. Electronic address:
High-dose oral minoxidil for the treatment of androgenetic alopecia.
Actas Dermosifiliogr
March 2025
Servicio de Dermatología, Unidad de Tricología, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, España; Unidad de Tricología y Trasplante Capilar, Clínica Grupo Pedro Jaén, Madrid, España.
Low-dose oral minoxidil (≤ 5 mg daily) has emerged as an effective off-label treatment for androgenetic alopecia, outperforming topical minoxidil in terms of adherence. However, the optimal dose has not yet been determined, and high doses may cause systemic adverse effects. This retrospective study of 57 patients evaluated the safety and efficacy profile of oral minoxidil at higher doses (> 5 mg).
View Article and Find Full Text PDFThe impact on body image and quality of life in breast cancer patients.
Rev Bras Enferm
March 2025
Universidade Federal de São Paulo. São Paulo, São Paulo, Brazil.
Objectives: to evaluate the quality of life and body image in women with breast cancer during chemotherapy, before and after interventions targeting body image.
Methods: we conducted a prospective cohort study with 47 women, utilizing both qualitative and quantitative data analysis.
Results: in the semi-structured interviews, 52.
Early-onset androgenetic alopecia (AGA) is a common, hereditary hair loss condition in men, often starting in the early twenties. It involves gradual thinning of hair, influenced by genetics, hormones, and other factors like smoking and family history. Early identification of these risks could support timely intervention.
View Article and Find Full Text PDFCorrection: Ritlecitinib, a JAK3 /TEC inhibitor, modulates the markers of celiac autoimmunity in alopecia areata and vitiligo patients.
Arch Dermatol Res
March 2025
Division of Gastroenterology and Hepatology, 200 1st Street SW, Rochester, MN, 55905, USA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!